Ewelina Hoffman

Dr. Ewelina Hoffman

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2014 in Journal of Controlled Release
Verified
Journal Article
Closed access
MJMarie-Christine Jones
Marie-Christine Jones
SJStuart A. Jones
Stuart A. Jones
YRYanira Riffo-Vasquez
Yanira Riffo-Vasquez
DSDomenico Spina
Domenico Spina
EHEwelina Hoffman
Ewelina Hoffman
LDLea Ann Dailey
Lea Ann Dailey

18 January 2019 in Journal of Chemical Information and Modeling
Verified
Journal Article
Closed access
BPBeatrice Pecoraro
Beatrice Pecoraro
Marco TutoneMarco Tutone
Marco Tutone
EHEwelina Hoffman
Ewelina Hoffman
VHVictoria Hutter
Victoria Hutter
AAAnna Maria Almerico
Anna Maria Almerico
MTMatthew Traynor
Matthew Traynor

19 May 2015 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
EHEwelina Hoffman
Ewelina Hoffman
AKAbhinav Kumar
Abhinav Kumar
VKVarsha Kanabar
Varsha Kanabar
MAMatthew Arno
Matthew Arno
LPLucas Preux
Lucas Preux
BFBen Forbes
Ben Forbes

24 May 2017 in Pharmaceutical Research
Verified
Journal Article
Open access
PDF file
EHEwelina Hoffman
Ewelina Hoffman
APAateka Patel
Aateka Patel
DBDoug Ball
Doug Ball
JKJan Klapwijk
Jan Klapwijk
VMVal Millar
Val Millar
VHVictoria Hutter
Victoria Hutter
Purpose Progress to the clinic may be delayed or prevented when vacuolated or “foamy” alveolar macrophages are observed during non-clinical inhalation toxicology assessment. The first step in developing methods to study this response in vitro is to characterize macrophage cell lines and their response to drug exposures. Methods Human (U937) and rat (NR8383) cell lines and primary rat alveolar macrophages obtained by bronchoalveolar lavage were characterized using high content fluorescence imaging analysis quantification of cell viability, morphometry, and phospholipid and neutral lipid accumulation. Results Cell health, morphology and lipid content were comparable (p < 0.05) for both cell lines and the primary macrophages in terms of vacuole number, size and lipid content. Responses to amiodarone, a known inducer of phospholipidosis, required analysis of shifts in cell population profiles (the proportion of cells with elevated vacuolation or lipid content) rather than average population data which was insensitive to the changes observed. Conclusions A high content image analysis assay was developed and used to provide detailed morphological characterization of rat and human alveolar-like macrophages and their response to a phospholipidosis-inducing agent. This provides a basis for development of assays to predict or understand macrophage vacuolation following inhaled drug exposure.

17 July 2019 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
APAateka Patel
Aateka Patel
EHEwelina Hoffman
Ewelina Hoffman
DBDoug Ball
Doug Ball
JKJan Klapwijk
Jan Klapwijk
RSRory T. Steven
Rory T. Steven
BFBen Forbes
Ben Forbes
‘Foamy’ alveolar macrophages (FAM) observed in nonclinical toxicology studies during inhaled drug development may indicate drug-induced phospholipidosis, but can also derive from adaptive non-adverse mechanisms. Orally administered amiodarone is currently used as a model of pulmonary phospholipidosis and it was hypothesized that aerosol administration would produce phospholipidosis-induced FAM that could be characterized and used in comparative inhalation toxicology. Han-Wistar rats were given amiodarone via (1) intranasal administration (6.25 mg/kg) on two days, (2) aerosol administration (3 mg/kg) on two days, (3) aerosol administration (10 mg/kg) followed by three days of 30 mg/kg or (4) oral administration (100 mg/kg) for 7 days. Alveolar macrophages in bronchoalveolar lavage were evaluated by differential cell counting and high content fluorescence imaging. Histopathology and mass-spectrometry imaging (MSI) were performed on lung slices. The higher dose aerosolised amiodarone caused transient pulmonary inflammation (p < 0.05), but only oral amiodarone resulted in FAM (p < 0.001). MSI of the lungs of orally treated rats revealed a homogenous distribution of amiodarone and a putative phospholipidosis marker, di-22:6 bis-monoacylglycerol, throughout lung tissue whereas aerosol administration resulted in localization of both compounds around the airway lumen. Thus, unlike oral administration, aerosolised amiodarone failed to produce the expected FAM responses.

1 January 2015 in Contemporary Oncology
Verified
Journal Article
Open access
EHEwelina Hoffman
Ewelina Hoffman
KGKatarzyna Gizelska
Katarzyna Gizelska
MMMarek Mirowski
Marek Mirowski
WMWojciech Mielicki
Wojciech Mielicki
The aim of the study : To analyze human breast cancer cell line MCF-7 and human malignant melanoma cell line WM-115 in order to characterize the cellular expression of CP and to evaluate whether ATO may affect this activity, as well as the viability of the cells. Material and methods : The...